Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $46.67 Average Price Target from Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average recommendation of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $46.6667.

A number of research firms have recently commented on AAPG. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company.

Ascentage Pharma Group International Price Performance

Shares of Ascentage Pharma Group International stock opened at $21.01 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a fifty-two week low of $18.56 and a fifty-two week high of $48.45. The firm has a fifty day moving average price of $23.39 and a two-hundred day moving average price of $26.07.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. Equities analysts anticipate that Ascentage Pharma Group International will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the company. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth about $391,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth about $383,000. XY Capital Ltd increased its position in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Finally, ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth about $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.